Of note, 51.1% of patients mounted detectable SARS-CoV-2-specific CD4+ T cell responses during the first week of infection, and 37.7% of patients mounted detectable SARS-CoV-2-specific CD8+ T cell responses during the first week of infection (Fig. 2e). The gene discussed is CD4; the disease is infection.